Proactive Investors - Run By Investors For Investors

Allergy Therapeutics upbeat after raising annual revenue forecasts

Manuel Llobet, chief executive at Allergy Therapeutics (LON:AGY), tells Proactive Investors revenues for the year ended June were slightly ahead of market expectations.

Llobet says the company is outperforming most competitors after the company said it had grown its market share by two percentage points to 12%.

The company expects strong revenue growth to continue for several years, it told investors.

Meet Victoria Oil & Gas plc, Avation PLC and Greatland Gold plc at our event, London, 07 September 2017. Register here »
View full AGY profile View Profile

Allergy Therapeutics plc Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use